Subscribe to Science Friday
In mid-April, President Trump issued an executive order to set aside funding and loosen the bureaucratic process at the FDA to fast-track psychedelic therapy research. One obscure psychedelic got a particularly bright spotlight: ibogaine.
Originating from the root bark of the iboga plant of central Africa, the psychedelic has shown promise for curbing opioid addiction and treating PTSD. But it also can be risky to take, and hasn’t made it to the medical mainstream like psilocybin or ketamine. So what’s the story with this drug?
Joining Host Flora Lichtman to talk about its history is neurologist and pharmacologist Deborah Mash, who secured the first FDA approval for clinical trials involving ibogaine in the 1990s. And to tell us how it fits in with the growing interest in medical psychedelics is Jane Hu, journalist for The Microdose newsletter. (Disclosure: Deborah Mash is founder and CEO of a company that’s developing a therapeutic drug based on ibogaine.)
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Jane C. Hu
Jane C. Hu is a journalist for the psychedelic science newsletter The Microdose, based in Seattle, WA.
Deborah Mash
Dr. Deborah Mash is professor emeritus of neurology and molecular and cellular pharmacology at the University of Miami School of Medicine. She is the also founder and CEO of DemeRx.
Segment Transcript
The transcript is being processed. It will be available 2-3 days after this story’s publication date.
Meet the Producers and Host
About Flora Lichtman
Flora Lichtman is a host of Science Friday. In a previous life, she lived on a research ship where apertivi were served on the top deck, hoisted there via pulley by the ship’s chef.
About Dee Peterschmidt
Dee Peterschmidt is Science Friday’s audio production manager, hosted the podcast Universe of Art, and composes music for Science Friday’s podcasts. Their D&D character is a clumsy bard named Chip Chap Chopman.